Cite
HARVARD Citation
Schafer, E. et al. (n.d.). A phase 1/2 study of talazoparib (BMN 673), an oral poly(ADP-ribose) polymerase inhibitor, plus temozolomide in children with refractory or recurrent malignancies: A Children's Oncology Group phase 1 consortium study (ADVL1411). European journal of cancer. pp. S48-. [Online].